SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Synta Pharmaceuticals
An SI Board Since February 2007
Posts SubjectMarks Bans Symbol
112 14 0 SNTA
Emcee:  keokalani'nui Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
62Unusual option volume this afternoon. fwiw <pre>CALL OPTIONS Expire at cSaulamanca-1/12/2009
61it is a bit bizarre, my guess is there was some leak in december before everythimopgcw-1/7/2009
60Hmmm? rather interesting announcement as this is the same I posted from 12/30 - Steve Lokness-1/7/2009
59official announcement today i guess...stock staying stong on above average volummopgcw-1/7/2009
58Well Roche has some confidence - although the headline is a bit much. Still 25 mSteve Lokness-12/30/2008
57Synta Announces Continuation of the SYMMETRYSM Trial Based on Evaluation of Indemopgcw-12/20/2008
56Synta Earns $15 Million from GlaxoSmithKline for Achieving Elesclomol Milestonesmopgcw-12/13/2008
55Synta Pharmaceuticals Reports Third Quarter 2008 Financial Results Business Wiremopgcw-11/15/2008
54Seeking Alpha CC Q3 2008 Earnings Call Transcript November 13, 2008 Q3 2008 Earmopgcw-11/14/2008
53Synta Earns $25 Million from GlaxoSmithKline for Achieving Elesclomol Milestonesmopgcw-10/18/2008
52yep, a couple director/investor purchases in Aug at $7.50ish..mopgcw-9/2/2008
51from transcript; <i>Safi Bahcall Yes. We have always been excited about Steve Lokness-9/2/2008
50q2 transcript: seekingalpha.commopgcw-9/2/2008
49Synta Pharmaceuticals (SNTA) (6.34 -1.46) Synta Pharmaceuticals Corp. (SNTA) on mopgcw-8/7/2008
48Message 24786644 thanks to doc.mopgcw-7/24/2008
47cc transcript: seekingalpha.commopgcw-5/28/2008
46Elesclomol Study Shows Significant Improvement in Progression-Free Survival for mopgcw-5/20/2008
45Synta Pharmaceuticals Reports First Quarter 2008 Financial Results Wednesday Maymopgcw-5/14/2008
44Seeking alpha part II: by: Ohad Hammer Synta (SNTA) launched a phase I trial mopgcw-5/1/2008
43Seeking Alpha: Will Synta Pharmaceuticals Break A 30 Year Old Record? by: Ohad Hmopgcw-4/28/2008
42Synta Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Resultmopgcw-3/20/2008
41>>Synta and GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designtuck-1/29/2008
40>> But also presentation of data on STA-9090 in 2008. Which is supposed totuck-1/17/2008
39Checking out slides from Lazard presentation last month, a couple of observationtuck-12/28/2007
38Synta Receives $80 Million Upfront Payment from GlaxoSmithKline Wednesday Decembmopgcw-12/5/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News